Emerging antithrombotic drugs for acute coronary syndrome.
Expert Opin Emerg Drugs
; 18(3): 307-18, 2013 Sep.
Article
en En
| MEDLINE
| ID: mdl-23848430
ABSTRACT
INTRODUCTION:
Acute coronary syndrome (ACS) encompasses acute myocardial infarction (MI) and unstable angina. Activation of platelets and coagulation cascade plays a central role in the development of ACS. Over the past decade, there have been substantial improvements in the strategies for secondary prevention of ACS, including the development of more potent oral antiplatelet agents such as prasugrel and ticagrelor. However, therapies with even better efficacy and safety profiles and more rapid onset and offset of action would be desirable. AREAS COVERED This review discusses the advantages and disadvantages of the currently available antithrombotic agents and describes the findings from recent clinical trials of three novel agents; cangrelor (an intravenous P2Y12 receptor antagonist), vorapaxar (protease-activated receptor-1 inhibitor) and rivaroxaban (an oral factor Xa inhibitor). EXPERT OPINION Cangrelor appears more promising than clopidogrel when a very rapid onset and reversal of antiplatelet effect is needed. Vorapaxar in addition to standard oral antiplatelet therapy was effective in patients with prior MI, but was not safe in patients with a prior stroke. Low dose rivaroxaban decreased cardiovascular events and mortality in patients post-ACS compared to placebo, although bleeding was increased.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Inhibidores de Agregación Plaquetaria
/
Síndrome Coronario Agudo
/
Fibrinolíticos
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Emerg Drugs
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos